


# **IMI JU 3rd Call for proposals**

# FOSTERING PATIENT AWARENESS ON PHARMACEUTICAL INNOVATION


Workshop

Moderator: Fatiha Sadallah





- This workshop will focuses on the scientific aspect of the topic
- Applicants can get acquainted with the IMI Call and to facilitate your work when applying
- We will present and explain the needs and expectations for this topic
- This process aims at promoting transparencies and fairness by providing the same information to all
- This session is video recorded, so please speak in the microphone, also when asking questions





- Objectives of the Project
  - All scientific objectives need to be addressed
- Need for public-private collaborative research
- Structure of the Project
  - The given structure is flexible and allows for innovative project design proposals
- Expected contribution of the applicants
- Contribution of EFPIA participants
- Key deliverables
  - The participants are expected to make key contributions on the defined deliverables in synergy with the EFPIA consortium






#### Overall objectives

Build innovative information programmes for different **stakeholders** involved on:

- the biomedical research and the processes leading to drug approval
- the multiple facets of personalized and predictive medicine
- rational approach to drug safety and risk benefit assessment of novel drugs
- the importance of health technology and pharmacoeconomics assessment in modern medicines
- the design and objectives of clinical trials
- the synergies between innovative medicines and other strategies to enhance patient-centred chronic disease management





### Need for public-private collaborative research

Existing information programmes on drug development are rather **fragmented**, **limited in scope**, there is a need for broader **consolidated approach** involving patient organisations, pharmaceutical companies and academic research organisations

The Innovative Medicines Initiative offers a unique opportunity to bring together all stakeholders to jointly work in an open and transparent way on improving the understanding of pharmaceutical research and development





• Suggested architecture of the full project proposal


The given structure is flexible and allows for innovative project design proposals. All the objectives should be addressed.

#### **Work Package 1: Project management**

- deliver alliance management, project management, governance and support

#### **Work Package 2: Network implementation**

- develop of a pan-European network of patient organisations and pharmaceutical companies covering a broad range of disease areas and geographical regions
- development of processes for linking to additional national and European stakeholders





#### Work Package 3: Needs assessment and gap analysis

- provide a detailed analysis of needs and existing programs /information sources

#### Work Package 4: Course content development

- develop information documents and website material in a language suitable for the general public
- provide translation of information documents into relevant major European languages

#### **Work Package 5: IT-Infrastructure**

- develop a robust IT-infrastructure for the content platform





#### **Work Package 6: Quality control**

- deliver a sustainable infrastructure for the training delivery, including methods for measuring the input and success of the programme

#### **Work Package 7: Future topics**

- propose new concepts for active involvement of patients in pharmaceutical R&D projects
- develop ideas for making information material available to other audiences beyond patient organisations






- Applicant Consortium is expected to:
- gather the multidisciplinary expertise necessary to conceive and implement the informational activities together with patient organizations representative of major disease areas across the European Union
- address all areas making key contribution on the defined deliverables in synergy with the EFPIA consortium





- The EFPIA participants\* will contribute by:
  - developing and implementing informational activities together with the other consortium partners
  - participating in the overall organisation and governance of the project
  - supporting translation activities



<sup>\*</sup>Astra Zeneca, GlaxoSmithKline, Roche, Bayer Schering Pharma, Novartis, Genzyme, Novo Nordisk, Amgen, Esteve, Merck KGaA, Pfizer



## Expected key deliverables

- establishment of a multidisciplinary and multilingual network of experts including patient advocacy groups to conceive and implement balanced information programs for patients, carers and other lay audiences interested in health policy
- establishment of an information programme to be available in a minimum of 6 major European languages
- implementation of informational strategies and activities based on novel information and communication technologies, targeting large audiences across Europe
- establishment of methods to assess and monitor the understanding and perception of pharmaceutical research linked to the development of new medicines





## **IMI Scientific Manager**

Fatiha Sadallah

Fatiha.Sadallah@imi.europa.eu

infodesk@imi.europa.eu

www.imi.europa.eu


#### Partner search tool:

www.imi.europa.eu/content/partner-search





- A Webinar on the Topic will be scheduled soon
- Instructions on how to participate will be available on the IMI website
- During the Webinar the Topic presentation will be repeated and it will be possible to ask questions to via a chat function





Thank you for your attention

http://imi.europa.eu

